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Abstract
Glucocorticoids (steroids) are an integral part of chemotherapy treatment; however,
steroids can cause hyperglycemia. There is no established protocol for the identification and
treatment of steroid induced hyperglycemia in the literature. Literature does show steroid
induced hyperglycemia is best identified by checking glucoses throughout the day following
steroid administration. Furthermore, the best treatment for steroid induced hyperglycemia is
basal/bolus insulin therapy. The prevalence of steroid induced hyperglycemia needs to be
established to support the implementation of a steroid induced hyperglycemia protocol in
oncology patients. A retrospective chart review of all patients 18 years and older admitted to
Hematology and Hematopoietic Stem Cell Transplant services over a three-month period was
conducted to determine the prevalence of steroid induced hyperglycemia at a rural tertiary
hospital. Results: Prevalence of steroid induced hyperglycemia was 37.9%. However, only
16.1% were ordered glucose monitoring throughout the day and only 18.6% received any
antidiabetic medications during hospitalization.

Keywords: steroid induced hyperglycemia, steroids, chemotherapy, hospitalization, oncology,
hyperglycemia
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Chapter 1 - Introduction
Background/Problem
Glucocorticoids (steroids) are medications used to treat various conditions during
hospitalization, including inflammation and immunosuppression. Glucocorticoids are prescribed
for oncology patients treated for cancer as part of chemotherapy treatment. The therapeutic
effects of glucocorticoids with chemotherapy include controlling chemotherapy induced nausea
and vomiting, preventing an allergic reaction to blood transfusion products or medications,
increasing appetite, reducing inflammation, treating pain, treating dyspnea, and killing cancer
cells and shrinking tumors as part of chemotherapy (Carter, 2020). A negative side effect of
glucocorticoids is hyperglycemia or elevated blood glucose levels. Glucocorticoids cause
hyperglycemia by augmentation of hepatic gluconeogenesis, alteration of receptor and postreceptor functions, and inhibition of glucose uptake in adipose tissue (Saag & Furst, 2021).
Hyperglycemia leads to adverse patient outcomes including higher mortality rates, increased
hospital length of stay, more likely to require admission to ICU, more likely to require
transitional care or nursing home placement at discharge (Umpierrez et al., 2002).
Hyperglycemia caused by steroids is called steroid induced hyperglycemia (SIH) and is
also associated with poor clinical outcomes and treatment related morbidities (Umpierrez et al.,
2002). Since oncology patients being treated for cancer are often prescribed steroids as part of
chemotherapy treatment, they are one of the most affected populations of SIH. Detection of
hyperglycemia can be found with daily lab work or blood glucose monitoring via fingerstick
glucose. However, blood glucose monitoring is often not ordered in this population. In addition,
there is no specific protocol for a hospital to follow to identify and manage steroid induced
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hyperglycemia. Unidentified hyperglycemia often results in a variability of treatment, suboptimal
glycemic control, and a gap in the timeliness of therapy.
A study by Umpierrez et al. (2002), looked at the prevalence of diabetes and
hyperglycemia in hospitalized patients to determine the effects of newly diagnosed
hyperglycemia on survival and functional outcome after adjusting for known prognostic factors.
The results showed that in-hospital hyperglycemia is a common finding and is an important
marker of poor clinical outcomes and mortality in patients with and without a history of diabetes
(Umpierrez et al., 2002). Therefore, identification and management of steroid induced
hyperglycemia in oncology patients treated with steroids is imperative.
Conceptual Framework
Donabedian’s Quality Framework evaluates the quality of care by assessing structure,
process, and outcomes (McDonald et al., 2007, Chapter 5). The structure looks at the setting in
which health care is provided while the process assesses the care delivery and care coordination.
Structure and process lead to health outcomes. Steroid induced hyperglycemia leads to negative
health outcomes; therefore, it is imperative to look at structure and process to improve care and
thus improve health outcomes and decrease costs to health care organizations and insurance
companies.
Cost of Hyperglycemia
The cost of steroid induced hyperglycemia has not been specifically identified in any
literature; however, the cost of diabetes has been established. Patients with steroid induced
hyperglycemia may have a history of diabetes or the hyperglycemia is new onset and related to
steroid effect. For those with a history of diabetes, the estimated total annual cost of diagnosed
diabetes in 2017 was $372 billion, with inpatient hospital care comprising 30% of the total cost
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(American Diabetes Association [ADA], 2018). Pennsylvania is equally affected by diabetes,
with an estimated $9.3 billion spent on direct medical expenses in 2017 for those diagnosed with
diabetes (American Diabetes Association [ADA], 2021b). Uncontrolled hyperglycemia,
including prolonged steroid induced hyperglycemia, can lead to the diagnosis of diabetes.
Diabetes is a leading metabolic disorder affecting an estimated 10.5% of the total United States
(U.S.) population and 13% of U.S. adults aged 18 years and older, and another estimated 2.8% of
the adult U.S. population has undiagnosed diabetes (Centers for Disease Control and Prevention
[CDC], 2020). Diabetes was the seventh leading cause of death in 2017 (ADA, 2018). Therefore,
identification and management of steroid induced hyperglycemia is essential.
Glucose Monitoring
Identification of steroid induced hyperglycemia in oncology patients is achieved with
blood glucose monitoring and should be initiated on all hospitalized patients receiving steroids.
Based on the metabolic effects of steroids, postprandial glucose monitoring offers the greatest
diagnostic sensitivity for identifying hyperglycemia. Testing four times per day, before meals,
will help identify any hyperglycemia caused by the steroids. Fasting glucose monitoring is not a
reliable diagnostic method for identifying steroid induced hyperglycemia and testing fasting
glucose only could result in underdiagnosed steroid induced hyperglycemia.
Identification and Treatment of Steroid Induced Hyperglycemia
The American Diabetes Association does not provide specific guidelines for the
identification or management of steroid induced hyperglycemia, nor does any other professional
diabetes/endocrinology organization. Providers prescribing chemotherapy focus on the effects of
chemotherapy on treating the illness, not necessarily secondary consequences such as
hyperglycemia from steroids.
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PICOT Statement
Are hospitalized oncology patients who have received steroids compared to those who
have not received steroids at increased risk of hyperglycemia? We will also examine the
frequency of blood glucose monitoring, determine average fasting glucose and average overall
glucose during the hospital stay, and the use of any antidiabetic medications.
Methodology
Three months of retrospective data will be collected from the electronic health record. A
list of patients meeting the inclusion criteria will be de-identified and given a unique number.
Demographic data collected will include age, self-identified gender, race, and ethnicity.
Additional data collected will include the status of hyperglycemia (glucose >/= 200 mg/dL),
frequency of glucose monitoring, use of antidiabetic medications, average fasting glucose, and
average glucose. Data will be analyzed to determine if there is a statistically significant
association between the reception of steroids and the presence of hyperglycemia.
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Chapter 2- Literature Review
Overview
The literature review covers the topics of prevalence, health outcomes, glucose
monitoring, treatment with basal and bolus insulin, treatment with basal insulin only, treatment
with bolus insulin only, treatment with metformin, and education regarding identification and
management of steroid induced hyperglycemia in hospitalized patients.
The Review of the Literature
The literature review process started with searching the following electronic databases:
PubMed, CINAHL and Cochrane. Keywords and phrases searched were chemotherapy,
hospitalized, inpatient, hyperglycemia, drug therapy, cancer treatment, pharmacotherapy, insulin
therapy, non-insulin therapy, hyperglycemia therapy, hyperglycemia drug therapy, steroid
induced hyperglycemia, glucocorticoid, steroid induced diabetes, chemically induced
hyperglycemia, and chemically induced diabetes mellitus. The terms were used as both keywords
and MeSH terms. Initial filters applied included English language, Adult (18+years), and
publication date from 2016-2021. A total of 42 articles were reviewed, but only eight articles
were appropriate for the literature review. These eight articles all had the keywords: steroid,
chemotherapy, hospitalization, and hyperglycemia. Reference lists of articles were reviewed for
any relevant studies not obtained through original search in the database. Three additional
articles were identified with the keywords: steroid, chemotherapy, and hyperglycemia – a total of
11 articles utilized for this literature review.
The negative health outcomes of steroid induced hyperglycemia have been established in
the literature; however, there is limited research on the prevalence of steroid induced
hyperglycemia in the inpatient setting (Umpierrez et al., 2002). There is also a lack of consensus
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regarding the most effective management option for steroid induced hyperglycemia, particularly
for patients hospitalized for cancer. Most of the articles were retrospective chart reviews.
Prevalence of Steroid Induced Hyperglycemia
The retrospective review by Donihi et al. (2006) reported that 66 out of 617 patients
admitted to a general medicine service received high dose corticosteroids, but only 50 out of the
66 had glucose measurement. Hyperglycemia was recorded in 64% of the 50 patients (Donihi et
al., 2006). In a retrospective review by Healy et al. (2017), the prevalence of steroid induced
hyperglycemia was 39% of 168 patients in an inpatient, hematologic setting. Healy et al. (2017)
analyzed hospitalized patients admitted to specific hematology/bone marrow transplant services,
while Donihi et al. (2006) analyzed hospitalized patients admitted to a general medical service
where steroids could have been utilized for a condition unrelated to an oncology diagnosis. Fong
& Cheung (2013) also looked at the prevalence of steroid induced hyperglycemia in non-diabetic
hospital patients where a protocol for glucose monitoring was implemented previously. In this
study, 48% of the 80 patients developed steroid induced hyperglycemia (Fong & Cheung, 2013).
In a more extensive retrospective study of hospitalized patients, 33.5% or 812 out of 2525
patients developed steroid induced hyperglycemia (Delfs et al., 2020).
Health Outcomes with Steroid Induced Hyperglycemia
Delfs et al. (2020) did a large forty-month retrospective study to assess the outcomes of
hospitalized patients with glucocorticoid-induced hyperglycemia while looking at secondary
endpoints of death, cardiovascular events, and infections. Mortality was not noted to be higher in
patients with steroid induced hyperglycemia; however, secondary endpoints identified oncology
patients receiving steroids as a significant covariable for hyperglycemia along with advanced age
and endocrinology patients receiving steroids for treatment of adrenal insufficiency (Delfs et al.,
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2020). Patients with steroid induced hyperglycemia had more cardiovascular events and the
infection rate was higher (Delfs et al., 2020).
Glucose Monitoring
In the retrospective analysis completed by Fong & Cheung (2013), only 38 of the 80
patients were started on glucose monitoring the same day steroids were initiated and 19 patients
were started on glucose monitoring the following day. Of these patients, 57 patients who did
have glucose monitoring within the first 48 hours, 94% developed hyperglycemia within 48
hours of starting on steroids. In another retrospective review, only 50 out of 66 patients
documented glucose measurements while receiving high dose corticosteroids (Donihi et al.,
2006). A retrospective review of 30 genitourinary (GU) cancer patients receiving corticosteroids
as part of chemotherapy showed a mean incidence of blood glucose monitoring in 19% of the
patients with diabetes and 76% in patients without diabetes (Rowbottom et al., 2015).
Rowbottom et al. (2015) concluded that all patients should be monitored for elevated glucose
levels to optimize patient care.
Basal and Bolus Insulin
The circadian pattern of hyperglycemia induced by steroids given daily in the morning
predominantly causes hyperglycemia in the afternoon and evening, followed by normalization of
glucose overnight with little to no effect on fasting glucose (Suh & Park, 2017). Radhakutty et al.
(2017), Spanakis et al. (2014), and Burt et al. (2015) all assessed the use of basal-bolus insulin
for the treatment of steroid induced hyperglycemia in hospitalized patients.
The randomized control study by Radhakutty et al. (2017) did not show any significant
difference in efficacy or safety between isophane-based insulin regiment versus glargine-based
insulin regimens. Spanakis et al. (2014) completed a retrospective chart review of 58 non-
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critically ill hospitalized diabetic patients receiving steroids in which only 20 patients achieved
normoglycemia during admission. The normoglycemia patients required a slightly higher total
daily dose of insulin per kilogram bodyweight with a significantly higher percentage of
nutritional insulin and a significantly lower percentage of correctional and basal insulin
(Spanakis et al., 2014). Similarly, Burt et al. (2015) completed a cross-sectional study of 66
hospitalized diabetic patients, including 24 patients taking prednisone and 42 patients not on any
steroids treated with a basal-bolus insulin protocol. The results showed that the patients taking
prednisolone required a significantly higher total daily dose of insulin compared to control (Burt
et al., 2015). The extra insulin requirements were at 1200 hours and 1700 hours, which
corresponds to the circadian pattern of hyperglycemia with steroids.
In a retrospective study, Gosmanov et al. (2013) compared basal-bolus inulin with sliding
scale insulin in treatment of forty patients with hematologic malignancies treated with high dose
dexamethasone. The basal-bolus regimen resulted in an average blood glucose reduction of 52
+/- mg/dL during therapy, which was statistically significant compared to the sliding scale
insulin regimen. In another study focusing on diabetic patients with steroid induced
hyperglycemia during cancer treatment, patients were started on a basal-bolus insulin regimen
with 25% basal insulin and 75% bolus (prandial) insulin (Brady et al., 2014). While the daily
average blood glucose improved significantly for these patients as their insulin doses increased,
glucoses remained above goal.
Currently, the Endocrine Society Clinical Practice Guidelines recommend starting insulin
at 0.3-0.5 units/kg for hospitalized patients with hyperglycemia (Umpierrez et al., 2012).
However, based on the studies above, patients with steroid induced hyperglycemia require
significantly more insulin. Radhakutty et al. (2017) found that an initial daily insulin dose of 0.5
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units/kg body weight is safe in hospitalized patients with prednisone-induced hyperglycemia.
Patients who achieved normoglycemia in the Spanakis et al. (2014) study required 0.8
units/kg/day. The normoglycemia patients required a significantly higher percentage of
nutritional insulin and a significantly lower percentage of correctional and basal insulin
(Spanakis et al., 2014). The patients with steroid induced hyperglycemia in the Burt et al. (2015)
required approximately 0.7 units/kg/day. Still, they had hyperglycemia in the afternoon and
evening, indicating a higher dose is required to achieve euglycemia.
In the two studies focusing on steroid induced hyperglycemia in patients receiving cancer
treatment, the total units/kg daily dose was higher. In the Gosmanov et al. (2013) study, patients
receiving bolus-basal insulin regimens were started at an average daily dose of 0.66 units/kg. By
the end of the study, they received a mean dose of 1.2 units/kg/day without any hypoglycemia.
Similarly, patients in the Brady et al. (2014) required an average insulin dose of 1-1.3 units/kg.
Despite the increased insulin requirements, the number of patients achieving euglycemia was not
noted in these studies.
Basal only
Basal-bolus insulin is the best treatment for steroid induced hyperglycemia; however,
numerous basal insulins have varying pharmacodynamic properties. Neutral protamine Hagedorn
(NPH) insulin onset is two to four hours, peaks four to twelve hours later, and is effective 12-18
hours. NPH mimics most steroids’ onset, peak, and duration of most steroids, making it the
preferred choice of basal insulin for steroid induced hyperglycemia based on pharmacodynamics.
Dhital et al. (2012) specifically compared the effect of NPH versus glargine as the basal insulin
used to manage steroid induced hyperglycemia in diabetic patients during hospitalization. The
results showed NPH and glargine were equally effective; however, the NPH cohort required less
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total daily dose of insulin. The NPH cohort required approximately 0.27 units/kg for basal
insulin, while the glargine cohort required 0.34 units/kg. The NPH cohort also required less
bolus insulin at 0.26 units/kg versus 0.36 units/kg for the glargine cohort. So overall, the NPH
group required approximately 0.53 units/kg daily, while the glargine group required
approximately 0.7 units/kg daily. As noted previously, in the Radhakutty et al. (2017) study, no
difference was seen between the isophane based insulin regimen versus the glargine-based
insulin regimen. A further breakdown of the total daily dose was not differentiated.
Sliding Scale Insulin
Sliding scale insulin is usually part of the bolus part of a basal-bolus insulin regimen and
provides guidance on the amount of insulin needed to treat hyperglycemia; however, sliding
scale insulin can also be used solely for the treatment of hyperglycemia. Health care institutions
use sliding scale insulin frequently as it is easy and convenient. However, it does not deliver
insulin in a physiologic manner, leading to fluctuations in glycemic levels. Unfortunately, there
is limited data to compare the use of basal/bolus insulin regiment versus sliding scale insulin.
Umpierrez et al. (2012) did a prospective randomized clinical trial to compare the
efficacy and safety of basal-bolus insulin with that of sliding scale insulin in non-critically ill
patients with type 2 diabetes. Based on the pharmacodynamics of insulin, sliding scale insulin
treats hyperglycemia after it has already occurred instead of preventing the occurrence of
hyperglycemia. The results did show that treatment with basal-bolus insulin regimen resulted in a
significant improvement in glycemic control compared with that of sliding scale insulin only
regimen.
Gosmanov et al. (2013) conducted a retrospective chart review of diabetic patients with
hematologic malignancies who received dexamethasone to determine whether a basal-bolus
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insulin (BBI) regiment was superior to a sliding scale insulin regimen for management of
hyperglycemia. This study showed that the basal-bolus regimen resulted in an average blood
glucose reduction of 52 +/- 82 mg/dL during the study while the sliding scale insulin regimen
resulted in an average blood glucose increase of 128 +/- 77 mg/dL, which was statistically
significant (Gosmanov et al., 2013). Both studies confirm that the basal-bolus insulin regimen is
safer and more effective in treating steroid induced hyperglycemia than sliding scale insulin
alone.
Metformin
First line therapy for patients diagnosed with type 2 diabetes or prediabetes, includes
lifestyle modifications such as meal planning, weight loss, and exercising. The second line of
treatment is with the medication metformin. Metformin lowers blood sugar levels by decreasing
the amount of glucose produced by the liver and increasing insulin sensitivity to absorb glucose
more readily. Based on pharmacodynamics, metformin could be an option to prevent steroid
induced hyperglycemia. In a prospective randomized controlled trial, Ochola et al. (2020)
assessed metformin’s effectiveness in preventing steroid induced hyperglycemia among
hematological cancer patients. In this study, non-hyperglycemic hematological cancer patients
receiving prednisone-based chemotherapy were randomized to receive metformin 850 mg once
then twice daily for two successive weeks or to the control group receiving standard care
(Ochola et al., 2020). Fasting and 2-hour postprandial fingerstick glucose tests were drawn
weekly for a total of four weeks. Eighteen out of 24 patients completed the study. Eight out of
eleven patients developed prediabetes in the control group, while only one out of seven patients
in the treatment group developed prediabetes (Ochola et al., 2020). The treatment group had a
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statistically significant improvement in mean 2-hour postprandial blood sugar readings in weeks
2, 3, and 4 of the study (Ochola et al., 2020).
Education
While treating steroid induced hyperglycemia is important, recognizing the need for
monitoring blood glucose in patients and initiating proper treatment is equally important. Nurses
can be proactive in screening patients for hyperglycemia, particularly in those with no known
history of diabetes because these patients are often asymptomatic with hyperglycemia.
De Vos-Schmidt & Dilworth (2014) developed a protocol specifically for patients on
corticosteroids during chemotherapy. All patients who received steroids as part of their day one
treatment regimen were screened with a two-hour postprandial fingerstick glucose level on day
two of the first chemotherapy cycle. No further intervention was indicated if the two-hour
postprandial blood glucose was less than 140 mg/dL. If two-hour postprandial blood glucose was
140-200 mg/dL, patients were provided with an educational intervention. As part of the
education, the patient was given a glucometer with one-on-one education on the use of the
glucometer, advised to check blood glucose two hours after the largest meal of the day, and
advised to limit carbohydrate consumption at one meal to 30 grams (De Vos-Schmidt &
Dilworth, 2014).
If the two-hour postprandial blood glucose level was 201 mg/dL or higher, they were
provided with the same educational intervention and started on a short acting insulin. The
patients were instructed to check blood sugars before every meal and follow the insulin
instructions provided (De Vos-Schmidt & Dilworth, 2014). The insulin regimen was based on a
formula of one unit for every 10 grams of carbohydrate and one additional unit for every 40
points above the target glucose of 130 (De Vos-Schmidt & Dilworth, 2014). In this quality
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improvement study of 30 patients, ten patients required intervention. Three patients only required
educational intervention while the other seven required educational intervention and insulin (De
Vos-Schmidt & Dilworth, 2014). Nine out of the ten patients requiring either intervention
achieve glycemic control for the remainder of the cancer treatments. De Vos-Schmidt &
Dilworth (2014) identified the importance of recognizing and managing hyperglycemia in
patients with cancer receiving treatment using a nurse driven protocol.
In a study by Sinaga & de Koeijer (2018), an evidenced practice protocol was
implemented to increase knowledge of both the nursing staff and patients on the importance of
blood glucose management during chemotherapy. A baseline audit showed that the current
standard of care was to notify the covering physician of any persistent hyperglycemia. However,
there were no set guidelines for target glucose or what constituted persistent hyperglycemia
(Sinaga & de Koeijer, 2018). Without an established protocol, insulin therapy was rarely utilized
for treatment, and patients were usually advised to contact their primary care provider for
diabetes management. Patients also did not receive any education regarding signs and symptoms
of hyperglycemia, monitoring glucose, or treatment of hyperglycemia (Sinaga & de Koeijer,
2018).
This study highlighted the importance of education for nursing staff and patients in the
identifying and treating steroid induced hyperglycemia. An evidenced based protocol for
identification and management of steroid induced hyperglycemia was created and implemented.
The nursing staff received education for identifying patients at increased risk of hyperglycemia,
signs and symptoms of hyperglycemia, and best management strategies (Sinaga & de Koeijer,
2018). The staff was advised on the importance of clearly assessing and documenting a patient’s
glucose levels prior to and during chemotherapy, along with identifying any signs or symptoms
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of hyperglycemia. Staff was encouraged to obtain a referral to a diabetes educator for patients
who had uncontrolled glucoses (Sinaga & de Koeijer, 2018). Following the implementation of
the evidenced based protocol, a repeat audit showed increased knowledge and awareness of both
staff and patients on the sign & symptoms of hyperglycemia, the importance of blood glucose
monitoring while receiving steroids, and the need to take appropriate action for treatment(Sinaga
& de Koeijer, 2018)(Sinaga & de Koeijer, 2018).
Gaps in the Research
Research regarding steroid induced hyperglycemia in hospitalized patients with cancer is
limited. The literature shows steroid induced hyperglycemia is treated in various ways, but
resultant glycemic control has not been clearly documented (Umpierrez et al., 2002). Most
studies are retrospective, with no specific protocol for the identification and management of
hyperglycemia. More prospective randomized controlled trials are needed.
Conclusion
Steroid induced hyperglycemia appears in patients regardless of whether they have a
prior history of diabetes, with a prevalence of 33.5-65% established in the literature (Umpierrez
et al., 2002). Recognition of steroid induced hyperglycemia is the first step to managing
hyperglycemia. The education of both staff and the patient is an integral part of the process. The
literature does indicate insulin is the best treatment for steroid induced hyperglycemia and basalbolus insulin regimen is the most effective for glucose management (Burt et al., 2015;
Radhakutty et al., 2017; Spanakis et al., 2014). However, recommendations regarding the
optimal dosing of basal-bolus insulin remain inconclusive. For non-diabetics, metformin can also
be considered to prevent prediabetes while on steroids (Ochola et al., 2020). Each organization
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should consider establishing a protocol that identifies steroid induced hyperglycemia and
initiates basal-bolus insulin sooner to achieve and maintain euglycemia.
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Chapter 3 – Methods
Retrospective Chart Review
This project was designed as a retrospective chart review of hospital records over three
months for all patients admitted to Hematology and Hematopoietic Stem Cell Transplantation
services at a tertiary health care center. The primary intention of the retrospective chart review
was to determine if hospitalized oncology patients who received steroids compared to those who
have not received steroids are at increased risk of hyperglycemia. Inclusion criteria included all
patients admitted to Hematology and Hematopoietic Stem Cell Transplantation service greater
than or equal to 18 years of age.
The data was collected via manual chart review from the electronic health record using a
pre-established database of patients meeting inclusion criteria obtained from the information
technology team. The primary investigator completed data collection.
Internal Review Board
Before collecting the data and for human subject protection, approvals were obtained by
submission to the Internal Review Board (IRB) of the research committee of the tertiary hospital.
This project coordinator also presented the proposal to the Nursing Research Committee (NRC)
for approval. After approval from both the NRC and IRB at the tertiary hospital (Appendix A),
an application and proposal were submitted to this project coordinator’s university IRB for
approval (Appendix B). Next, the primary investigator submitted an analytics intake request via
information technology portal at tertiary hospital for a list of medical record numbers for patients
meeting the inclusion criteria for this project. The turnaround time was approximately 30 days.
In conjunction with the Health Insurance Portability and Accountability Act (HIPAA) Privacy
Rule, the data was de-identified and given a unique number to mitigate privacy risk. The primary
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investigator was the only person accessing the medical record number and could matched to the
unique identifying number. To minimize risk of external knowledge of the medical record
number and the matched unique identifying number, the records were kept on a passwordprotected personal computer that is only in possession of the primary investigator. All
information used for this project will be destroyed after three years in a confidential manner.
Measures
Demographic data collected included age, self-identified gender, race, and ethnicity.
Additional data collected included the status of hyperglycemia (glucose >/= 200 mg/dL),
frequency of glucose monitoring, use of antidiabetic medications, average fasting glucose, and
average glucose.
The Centers for Medicare and Medicaid Services (CMS) measures inventory tool of
hospital harm – severe hyperglycemia assesses “the number of inpatient hospital days with a
hyperglycemia event (harm) per the total qualifying inpatient hospital stays for patients 18 years
of age or older at admission” (The Centers for Medicare and Medicaid Services [CMS], 2021, p.
1). This inventory tool was used to establish and identify hyperglycemia when collecting the data
for this study. Patients with one glucose reading > 200 mg/dL were identified as having
hyperglycemia. The charts were reviewed for whether the patient received any steroids during
hospitalization, regardless of the dose, timing, or indication.
The primary outcome of the retrospective chart review was to evaluate the incidence of
steroid induced hyperglycemia. The secondary outcomes from the chart review include a)
average fasting glucose, b) average glucose, c) frequency of glucose testing, d) use of
antidiabetic medication (e.g., insulin). The secondary outcomes were used to determine the

18
appropriate frequency of glucose testing and the type of intervention that may be most useful
when developing a protocol for implementation in the future.
Analysis
The data was analyzed using IBM SPSS Statistics (Version 27) predictive analytics
software. The data was analyzed to determine if there is a statistically significant association
between the reception of steroids and the presence of hyperglycemia. A hospitalized oncology
patient either received steroids or did not received steroids. The reception of steroids is a nominal
variable with two levels (yes vs. no). Based on the CMS definition, the patients with glucose
readings > 200 mg/dL was considered as having hyperglycemia. The status of hyperglycemia is a
nominal variable with two (yes vs. no) levels. A nominal variable has two or more categories,
but there is no intrinsic ordering to the categories (Stevens, 1946).
The data was also analyzed to look at the secondary outcome measures. Average fasting
glucose and average glucose are ratio variables. A ratio variable is one where there is order and
the difference between two values is meaningful and has a clear definition of 0 (Stevens, 1946).
When the variable equals 0, there is none of that variable. The frequency of glucose testing is a
nominal variable with two levels (daily vs. AC/HS). The use of an antidiabetic medication is a
nominal variable with two levels (yes. vs. no). An examination of test assumptions was
completed to assess for presence of multicollinearity that could affect analysis of data.
A univariate analysis was used for descriptive analysis of the data. Frequency tables
summarize the data, including the primary measure, the secondary measures, the predictor, and
the demographics. Next a bivariate analysis was completed to examine the relationship between
the dependent variable and independent variable as well as the relationship between the
dependent variable and the covariable. The chi-square test of independence was performed to
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determine if there is a statistically significant association between reception of steroids and status
of hyperglycemia, i.e., to determine if hospitalized oncology patients who have received steroids
are at increased risk for hyperglycemia, compared to those who have not received steroids (Field,
2013). The chi-square test of independence was also performed to determine if there is a
statistically significant association between frequency of glucose monitoring and reception of
antidiabetic medication to the status of hyperglycemia during hospitalization. A multivariate
analysis was completed to further assess the bivariate variables with statistical significance to
determine which variable is the strongest predictor of the dependent variable hyperglycemia,
which is the overall goal of this data analysis study. A binary logistics regression model was
used for the multivariate analysis. For any tests, a p-value less than 0.05 was considered
significant.
A priori power analysis based on the chi-square test of independence for determining if
there is a statistically significant association between reception of steroids (a nominal variable
with two levels: yes vs. no) and status of hyperglycemia (a nominal variable with two levels: yes
vs. no) was conducted to determine the minimum sample size required for this study using
G*power 3.1.9.4 (Faul, Erdfelder, Buchner, & Lang, 2009). Assuming a medium effect size
(Cohen’s w = 0.3) (Cohen, 1992) and a significance level of 0.05, the minimum sample size
required to detect a significant effect with 80% power is 88. Thus, chart reviews for at least 44
hospitalized oncology patients who have received steroids and 44 hospitalized oncology patients
who have not received steroids are required for this study. Figure 1 shows the results of power
analysis using G*power. Data was collected from 118 charts.
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Chapter 4 – Results
Data and Analysis
This study was a retrospective chart review and data analysis to determine the prevalence
of steroid induced hyperglycemia in patients admitted to a Hematology and Hematopoietic Stem
Cell Transplantation services at a tertiary health care center over a three-month period. Inclusion
criteria were all patients aged 18 years and older admitted to Hematology and Hematopoietic
Stem Cell Transplantation services between 7/1/2021-9/30/2021. Data examined included
demographics, administration of steroids, presence of hyperglycemia (glucose >200 ml/dL),
frequency of glucose testing, average glucose, average fasting glucose, and use of any
antidiabetic medications.
The IRB at both the medical center and education institution approved this project. The
project had support from the Hematology and Hematopoietic Stem Cell Transplantation services,
oncology pharmacist, endocrinology department director, and information technology.
Demographic Analysis
A descriptive analysis of demographics is listed in Table 1. The age ranged from 18-91
years with a mean of 60.38. Gender was almost equally divided, 48.3% of the 118 were male
while 51.7% were female. There was no variation in either race or ethnicity and all participants
were 100% white and non-Hispanic or Latino. A descriptive analysis of the categorical variable’s
steroid received during hospitalization, hyperglycemia during hospitalization, frequency of
glucose monitoring and reception of antidiabetic medication during hospitalization are listed in
Table 2. More than half of patients received steroids during admission (n=66; 66%) while
approximately a quarter of the patients developed hyperglycemia during admission (n=28;
23.7%). Most of the patients had fasting glucose monitoring (n=99; 83.9%) while the other
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16.1% (n=19) had glucoses monitored before meals and at bedtime. Similarly, 81.4% (n=96) did
not receive any antidiabetic medications during hospitalization while only 18.6% (n=22)
received any antidiabetic medications during hospitalization.
Descriptive analysis of the variable’s average fasting glucoses and average glucose
before meals/bedtime (AC/HS) during admission are listed in Table 3. The average fasting
glucose was 121.31 mg/dL (SD=26.248; MIN/MAX=68/252) and average AC/HS glucose was
152.30 mg/dL (SD=27.715; MIN/MAX=94/203).
Glucose Monitoring and Antidiabetic Medications
Bivariate analysis of the categorical variable’s steroid received frequency of glucose
monitoring and reception of antidiabetic medications with the dependent variable hyperglycemia
are listed in Table 4. Chi-square analysis indicated reception of steroids was associated with
hyperglycemia, X(2)=16/568, p<0.001. Chi-square analysis also indicated AC/HS glucose
monitoring and reception of antidiabetic medications were also associated with hyperglycemia,
X(2)=31.227, p<0.01 and X(2)=18.684, p<0.01, respectively.
Bivariate analysis of the continuous variable average fasting glucose and AC/HS average
glucose with the dependent variable hyperglycemia are listed in Table 5. An independentsamples t-test showed patients with fasting glucose monitoring who developed hyperglycemia
had a mean average glucose (M=146.57, SD=32.012) which was statistically higher than those
who did not develop hyperglycemia (M=113.46, SD=18.212), t(116)=-6.892, p<0.001. Likewise,
an independent samples t-test showed patients with AC/HS glucose monitoring who developed
hyperglycemia had a mean average glucose (M=162.93, SD=18.839) that was statistically higher
than those patients who did not develop hyperglycemia (M=120.40, SD=26.651), t(18) = -3.954,
p<0.001.
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Indicator of Hyperglycemia Analysis
A binary logistic regression analysis of the predictors to determine the strongest indicator
of hyperglycemia during hospitalization is shown in Table 6. The data showed the statistical
significance of the overall model X(3) = 46.814, p<.001. The individual predictor, reception of
steroids, showed those who received steroids during hospitalization were almost 21 times
(OR=20.990, 95% CI=3.576-123.216) more likely to develop hyperglycemia, X (1, N=118) =
11.363, p=0.001. Data also showed frequency of glucose monitoring was also statistically
associated with hyperglycemia, X (1, N=118) = 7.023, p=0.008.
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Chapter 5 - Discussion
For hospitalized oncology patients receiving steroids, there is limited data regarding the
incidence of steroid induced hyperglycemia (Rowbottom et al., 2015). There are no established
guidelines listed in the literature for the identification and management of steroid induced
hyperglycemia (Umpierrez et al., 2012). The tertiary hospital where this chart review was
completed also did not have any established guidelines for identification and treatment of steroid
induced hyperglycemia. Glucoses are typically elevated the most a few hours after steroid
administration; therefore, identification of steroid induced hyperglycemia is best identified by
measuring glucoses throughout the day (Suh & Park, 2017). Steroid effect on glucoses often
wears off in 24 hours, resulting in normal fasting glucoses when steroids are given in the
mornings (Suh & Park, 2017).
The prevalence of steroid induced hyperglycemia from the literature review ranged from
33.5-64% of hospitalized patients. This retrospective chart review confirmed the prevalence of
steroid induced hyperglycemia on one unit of hospitalized oncology patients at 37.9%, which is
consistent with the literature. This also means 62.6% of patients who received steroids did not
develop hyperglycemia during hospitalization. There were also three patients (5.8%) who
developed hyperglycemia but did not receive any steroids during hospitalization. It is unknown
what percentage of patients had underlying diabetes which could have contributed to
hyperglycemia.
The frequency of glucose monitoring identified in the literature review ranged from 45.775.7%; however, the differentiation between fasting glucose monitoring versus glucose
monitoring throughout the day was not specified. In this retrospective chart review, only 16.1%
of the patients had glucose monitoring throughout the day, before meals and at bedtime. The
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remaining patients only had fasting glucose readings available for review. The fasting glucoses
were not specifically ordered, but part of a basic metabolic panel (BMP) drawn every morning
for hospitalized patients. Due to the low percentage of patients having glucoses checked during
the day, patients with steroid induced hyperglycemia may not have been identified.
Additionally, only 18.6% of the patients received antidiabetic medications for treatment
of hyperglycemia in this retrospective chart review. The type of medication used was not
identified in this study; however, there were patients who had hyperglycemia, but no antidiabetic
medications prescribed.
Limitations
Project Methodology
This retrospective chart review did have some limitations. First, the same size was small.
While enough data was collected to identify statistical significance, a larger sample size would
better identify the prevalence of steroid induced hyperglycemia. While a total of 118 charts were
reviewed, patients may have been hospitalized more than once over the 3-month period reviewed
which could affect the data analysis. Another limitation was the retrospective nature of this
study. Retrospective studies have biases including selection and misclassification bias that can
impact the data collected and analyzed. Finally, this retrospective chart reviewed relied on the
data inputted into the electronic medical records, which could lead to inaccurate data.
Protocol Methodology
This tertiary hospital did not have any specific protocol for glucose monitoring or
hyperglycemia treatment in place which leads to the inconsistent ordering of both glucose
monitoring and antidiabetic medications. Additionally, there was no specific order for fasting
glucoses. The fasting glucose was just part of the daily basic metabolic panel ordered for the
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patient which means providers were not necessarily interested in monitoring glucose levels.
Since the steroid effect causes glucoses to peat 4-6 hours after administration, only monitoring
fasting glucoses may not capture all patients who developed steroid induced hyperglycemia.
Another limitation was the lack of cultural diversity. All patients self-identified as white
and non-Hispanic or Latino, which is most representative of the rural setting of this tertiary
hospital. Therefore, the results cannot be generalized to other hospital settings with more cultural
diversity.
Other Challenges
There were some challenges completing this retrospective chart review. Due to
contractual issues, data could not be collected or analyzed until ten days prior to the completion
date of this study. The primary investigator personally completed the data collection and data
analysis.
Future Recommendations
Glucocorticoids are an important part of chemotherapy treatment; however, treating
hyperglycemia during hospitalization is imperative to decrease mortality and poor clinical
outcomes. Based on this retrospective chart review, this tertiary medical center would benefit
from a protocol for identification and management of steroid induced hyperglycemia. A
subsequent quality improvement (QI) project should involve educating the oncology providers,
pharmacists, nursing staff and patients on the prevalence of steroid induced hyperglycemia,
importance of treating steroid induced hyperglycemia, and the signs/symptoms of
hyperglycemia. The protocol should include glucose monitoring and best practice treatment. As
previously discussed in the literature review, it is best to check blood sugars before meals and
throughout the day to identify steroid induced hyperglycemia (Suh & Park, 2017). Subsequently,
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if a patient develops hyperglycemia, insulin therapy should be initiated promptly using
basal/bolus insulin therapy as the best treatment option for steroid induced hyperglycemia (Burt
et al., 2015)(Radhakutty et al., 2017)(Spanakis et al., 2014). The new protocol should have
ongoing data collection and analysis using the parameters established from this retrospective
chart review.
Additional data can be examined for secondary outcomes to provide more information
regarding steroid induced hyperglycemia in the oncology population. These data points could
include the type of cancer, type of steroid prescribed, the dose of steroid prescribed, frequency of
steroid prescribed, type of insulin prescribed, preexisting diagnosis of diabetes, and which
medical service managed diabetes during admission.
Conclusion
This retrospective chart review identified the prevalence of steroid induced
hyperglycemia in oncology patients admitted to Hematology and Hematopoietic Stem Cell
Transplant services at a rural tertiary hospital over the three-month period. This study also
identified the lack of glucose monitoring and the lack of antidiabetic medications administered
during hospitalization. Establishing a protocol for identification and management of steroid
induced hyperglycemia in this population would help improve health outcomes and decrease
mortality.
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Table 1
Descriptive Statistics of Demographics
Variable

n

Minimum

Maximum

Mean

Age

118

18

91

60.38

Variable

n

%

57
61

48.3
51.7

118

100

118

100

Gender
Male
Female
Race
White
Ethnicity
Non-Hispanic or
Latino
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Table 2
Descriptive Analysis of Categorical Variables (N=118)
Variable

n

%

52
66

44.1
55.9

90
28

76.3
23.7

99

83.9

19

16.1

96
22

81.4
18.6

Steroid received during hospitalization
No
Yes
Hyperglycemia (Glucose >200) during
hospitalization
No
Yes
Frequency of glucose monitoring
Fasting
AC/HS*
Receiving antidiabetic medication during
hospitalization
No
Yes
Note: *AC/HS = before meals and at bedtime.
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Table 3
Descriptive Analysis of the Continuous Variables
Variable

M (SD)

MIN/MAX

Potential Scores

Average Fasting
Glucose

121.31 (26.248)

68/252

n/a

Average AC/HS
Glucose

152.30 (27.715)

94/203

n/a

Note. M = mean, SD = Standard deviation, Min = minimum, Max = maximum
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Table 4
Bivariate Analysis of Categorical/Categorical Variables – Chi-square (N=118)
Hyperglycemia (glucose >200) during hospitalization
No
Yes
Variable

n (%)

n (%)

Received Steroid

16.568 (1) **

No

49 (94.2)

3 (5.8%)

Yes

41 (62.2)

25 (37.9%)

Frequency of glucose
monitoring

31.227 (1) **

Fasting

85 (85.9)

14 (14.1)

AC/HS

5 (26.3)

14 (73.7)

Received antidiabetic
medications

18.684 (1) **

No

81 (84.4)

15 (15.6)

Yes

9 (40.9)

13 (59.1)

Note. ** (p<0.01)

X2 (df)
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Table 5
Bivariate Analysis of Categorical/Continuous Variables - Independent Samples t-test (n=118)
Hyperglycemia (glucose >200) during hospitalization
Variable
M (SD)
t (df)
Average Fasting Glucose
No

113.46 (18.212)

Yes

146.57 (32.012)

Average AC/HS glucoses
No
120.40 (26.651)
Yes
162.93 (18.839)
Note: (p<0.01 = statistically significant)

p

-6.892 (116)

0.00

-3.954

0.01
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Table 6
Binary Logistics Regression Analysis Examining Hyperglycemia
Variable

B (SE)

(X2)

OR (95% CI)

Steroid received
during hospitalization

3.044 (.903)

.001

20.990 (3.576-123.216) **

Frequency of glucose
monitoring

2.720 (1.027)

.008

15.188 (2.031-113.586)

.981 (.964)

.309

(.403-17.638)

Received antidiabetic
medication during
hospitalization
Note. ** (p<0.01)
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Figure 1
Power Analysis Using G*power
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